8-K filing — Perspective Therapeutics, Inc. (CATX)
Filed: 2026-11-06 AccNo: 0001193125-26-450709 Size: 17 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Perspective Therapeutics Announces Incremental Phase 1/2a Clinical Trial Data for [212Pb]VMT-α-NET
Perspective Therapeutics reported positive incremental data from its Phase 1/2a trial of [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, with plans for an end-of-Phase 2 meeting in early 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
Wedbush Adjusts Price Target on Perspective Therapeutics
Wedbush has revised its price target for Perspective Therapeutics to $9 from $11 while maintaining an Outperform rating.
RBC Downgrades Perspective Therapeutics to Sector Perform
RBC has downgraded Perspective Therapeutics to Sector Perform from Outperform and reduced its price target to $4 from $14.
Perspective Therapeutics Reports Clinical Trial Data and Hosts Conference Call
Perspective Therapeutics released clinical trial data for its radiopharmaceutical program and held a conference call on October 23, 2026, to discuss results presented at the ESMO Congress 2026.
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in